UK scientists are starting a trial to determine whether CBD can help in reducing psychotic symptoms in patients with Parkinsonism, which has provided a more effective means of treatment.

Scientists at Somerset are participating in national research to investigate whether cannabidiol (CBD) is effective in the treatment of psychotic symptoms in patients with Parkinsonism. Psychosis that occurs in approximately three out of every five individuals with the condition usually consists of hallucinations and delusions.

The Somerset NHS Foundation Trust is co-working with other centers in the UK to investigate whether CBD may provide a safer option than existing drugs, which have restricted efficacy and usability over time. The study will consist of 120 patients nationally, among them Devon and Cornwall.

CBD is a health supplement derived from the cannabis plant that has gained popularity. Although there is some evidence that it can be used to decrease psychosis, it is the first trial to directly focus on patients with Parkinson's.

The principal investigator, Dr. Sarah Cleaver, stated that the trial is a significant move towards providing better treatment options: "Psychosis can be a debilitating disease, and we have limited options currently." This research is very important for improving treatment options.

The volunteers will be assigned to one of the two treatments: CBD pills or placebo and the researchers will be closely observing the reactions during 12 weeks.